115
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Growth of Global Health Spending Share in Low and Middle Income Countries

      other

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Historical patterns of global health spending Over the past century medical technology has provided bold gains extending human longevity for almost several decades in most welfare economies worldwide. These public health victories came at the cost of huge increase in health spending. The USA, the largest health care market where total health expenditure (THE) grew from 4% of GDP to 15%, may serve as an example of such changes. The secular trend consisting of rising wages and incomes constitutes major factor in the rising resources dedicated to the medical care. Business cycle booms and recessions affected health care spending slowly and with a significant lag. In this sense health expenditures should not be compared to short term, quarterly or yearly fluctuations in Gross Domestic Product (GDP) but correlates well to “smoothed” income over the previous 3–6 years (Getzen, 1990). Growth of health expenditure is driven by several underlying issues: population birth rates, per-capita income, inflation and so called “excess growth” that is mostly explained by medical technology advances or increased patient demand for services. This “excess growth” is responsible for raising the share of health care in national GDP, and thus challenging fiscal sustainability. Evidence of excess growth is seen in health insurance premiums that persistently rise faster than tax revenues or wages. Isolated excess cost growth was the key underlying reason for the surmountable surge in health care costs visible in the United States since the late 1950s. Unlike the contemporary post WWII era, previous historical records testify of stable medical costs of about 4% of GDP from 1929 to the late 1950s. U.S. Census records of employment in clinical medicine and published consumer expenditure evidence from 1850–1950 show that these costs were mostly keeping pace with wages. If they were slightly exceeding wages it was only about 0.5% annually thus it took more than a century for them to double, much slower than the quadrupling from 1960 to 2000 (Getzen, 2000). Major causes of such a sudden rise in health expenditures were huge economic development, distinctively extended longevity, control of contagious diseases, rising availability of income used to fund research in medicine, effective financing instruments, and ultimately significant discoveries in medical technologies that supported public willingness for further investment into potential novel biological drugs, implants, robotic surgery, radiation therapy, organ transplants, and other wonder technologies (Getzen, 2014). With several decades delay, due to dissemination of knowledge and improved societal welfare across the globe, similar developments began at the far smaller scale in a large number of low and middle income world economies. Among 160 such nations in the beginning of 1990s long term trends have revealed 16 countries which made greater investments in health care and its core outcomes than most comparable nations. These countries were described by Goldman-Sachs as the world's leading emerging markets. They are listed under the acronyms BRICS (Brazil, Russia, India, China, South Africa) and Next Eleven (N-11: Bangladesh, Egypt, Indonesia, Iran, South Korea, Mexico, Nigeria, Pakistan, the Philippines, Turkey, and Vietnam). This ongoing evolution will most likely shape the appearance of global demand and supply of medical services in XXI century and we believe that therefore it deserves closer examination. Growth of health care spending in low and middle income countries since 1995 The last two decades have been particularly dynamic due to ending the Cold War and accelerated pace of globalization. Contemporary evolution was promising for most nations with average world THE rising from 5.7 to 6.8% GDP [a 19.3% gain or approximately 1% yearly increase over 19 years (Table 1)]. Since 1995 World Health Organization (WHO) has established and disseminated National Health Accounts (NHA) system worldwide. These efforts allowed reliable international comparison of financial flows among national health systems with diverse historical legacies. The World Bank (WB) introduced the measure of gross national income (GNI) classification of countries in 1987 with their Atlas method and GNI per capita indexed in US$ currency (World Bank Income Groups, 2015). Availability of national income per capita strongly influences health expenditure. The correlation is straightforward with a secular trend visible in long time horizons in most world regions. We applied historical lists of WB income classification to reveal patterns in global health spending. Participation of 160 low and middle income countries (as defined by WB in 1995) in global health spending (in million const. 2005 $US) was 10.7%. Nineteen years later the world was a much different place. Global welfare of nations recorded bold increases while 23 countries crossed the WB threshold for high income economies. The remaining 137 low and middle income countries (as defined by WB in 2013) were now spending 14.6% of global THE expressed in millions of constant 2005 $US. The landscape of national medical spending has evolved in favor of developing regions. The 160 countries classified as low and middle by WB in 1995 grew from 26.1% of global THE in 1995 to 39.7% in 2013. While high income economies still dominate the global landscape of medical spending, the growth of emerging economies has reduced their share of the total. Table 1 Transformation of Global Total Health Expenditure (THE) 1995–2013. Table based on WHO National Health Accounts data 1995–2013; Classification based on World Bank Historical Lists of Income level country groups 1995/2013 based on GNI per capita in US$ (Atlas methodology); Top tier Emerging Markets definition adopted based on Goldman-Sachs acronyms BRICs and Next-11. *WB Note: Income classifications are set each year on July 1 for all World Bank member economies, and all other economies with populations of more than 30,000. These official analytical classifications are fixed during the World Bank's fiscal year (ending on June 30), thus economies remain in the categories in which they are classified irrespective of any revisions to their per capita income data. The historical classifications used are as published on July 1 of each fiscal year. **Total of 13 countries/legal entities were not classified according to WB Income groups while three countries ceased to exist in 1995. In 2013 there were two of such non-classified entities listed together with five countries that ceased to exist. ***For a total of 18 countries inclusive of Japan 2013 data are still not released officially therefore closest year available (2012 data in most cases) was used. Joint total health expenditure of these countries excluding Japan remains significantly below 1% of global THE. ****Among the BRICS and Next–11 emerging markets THE data expressed in terms of constant 2005 $US are lacking for Russian Federation and Pakistan for the entire 19 years long observation period and therefore inclusion of this indicator among the emerging markets was omitted entirely due to absence of data for two large nations. Causes of changes and leadership of BRICs + next-11 emerging nations Jim O'Neil's grouping of BRICs was driven primarily designating those whose nominal and purchase power parity (PPP) adjusted GDP growth rates significantly outpaced those of most OECD nations before and during the worldwide economic recession. Similar ongoing development characterizes another group, identified by Goldman-Sachs' as the “Next Eleven.” Profound changes with deep and lasting impact to the global demand for and provision of healthcare services and associated expenditure have occurred. Rapid expansion of civil middle class in most of these societies has been a major underlying factor (Jakovljevic, 2015). Substantial gains in overall welfare are reflected in the expansion of health insurance coverage and diversity of medical services provided. Growth of purchasing power effectively improved affordability of advanced medical care that remains out-of-pocket expense. We witness continuing movement of global growth in health care markets from the established mature economies toward the emerging ones. Slower economic growth in most saturated high-income markets is a contributing factor. Consumer demand for medical services remains larger in traditional wealthy countries, but their share has been decreasing steadily for at least two decades. Total amount of health care spending among BRICS and Next-11 nations became approximately six fold stronger since 1995. Share of Global Health Spending (million current US$) of these emerging nations grew almost two and a half times. This pace of development is far faster compared to that of vast majority of remaining low and middle income countries across the globe. If we observe per capita health spending it appears that general government expenditure on health and private expenditure is consistently stronger among BRICS compared to N-11. Such a historical trend was actually present prior to 1990s and spending differentials continued to exist as paths diverted even further in recent years. Out-of-pocket (OOP) expenditure on health is a significant outlier in this regard. Although both country group averages were similar at the start, N-11 OOP spending soon exceeded BRICs. These facts indicate better success rates among the BRICs in terms of reimbursement policies and insurance coverage over the past 20 years (Jakovljevic, 2014). Prospects for the future Observation of health spending trends over 20 years is still insufficient to understand a “medical transformation” taking place in major national health systems worldwide. Limitations to our judgment might be imposed by reliability and comparability of large international datasets as well (Rayne, 2013). Nevertheless contemporary transformation of global health spending lays grounds for some forecasts on likely scenarios for the future. Low and middle income countries are likely to become more relevant contributor to the global health care market in the long run. Minor proportion of these countries will likely become high income economies over the next decade. Vast majority of them will continue to experience serious obstacles to the fiscal feasibility of their national health systems. Crucial challenges will remain population aging, prosperity disease and rapid urbanization leaving vulnerable rural areas. Universal health insurance coverage will still be a distant policy target for most of these governments with the notable exception of Russian Federation (Jakovljevic et al., in press). Large out of pocket expenses and informal payments will leave ordinary citizens, living close to the poverty line, vulnerable to the illness-induced catastrophic household expenditure (McIntyre et al., 2006). In some world regions with still young populations, communicable diseases control and satisfactory maternal and neonatal medical care provision shall still be a long way ahead (Barik and Thorat, 2015). Regardless of all the aforementioned weaknesses of developing world regions, it appears that most successful among these nations will become even more important players in global health arena. Heavily domination of People's Republic of China (He and Meng, 2016) followed by India in medical spending worldwide will exceed that of all other emerging markets combined. As we approach 2050 it is highly likely that financing of health care in top tier emerging nations will converge toward OECD average in terms of its effectiveness and affordability of medical care to the ordinary citizen (Jakovljevic, 2016). Major imperatives for national policy makers shall remain how to achieve universal health coverage, what services would be covered by basic insurance package and at what cost. Future research in the field should primarily be focused on key causes of out-of-pocket medical spending growth, deepening social gap among the rich and poor communities leading to health inequalities and effectiveness of contemporary policies in low and middle income countries. Data report methodology Public data sources used were WHO issued Global Health Expenditure Database relying on NHA records: http://apps.who.int/nha/database/Select/Indicators/en and World Bank (WB) Income Groups; Historical country classifications based on Atlas method: http://data.worldbank.org/about/country-and-lending-groups. Filters applied to these extensive data sources were indicators referring to the national level and Global Total Health Expenditure (THE) expressed in following units: million constant 2005 $US, million current US$, million current PPP international $US and THE percentage share of national Gross Domestic Product available (GDP). Data were acquired based on reported values to the WHO and WB by the national authorities as well as independent assessments and calculations provided by WHO and WB and officially released in respective years. Readers are free to access and reuse these publicly available data at the links provided above. Author contributions MJ and TG have jointly developed the research questions, study design, did all the calculations and prepared manuscript for this Data report. Therefore, they share the first authorship in this paper. Conflict of interest statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts?

          This paper presents the findings of a critical review of studies carried out in low- and middle-income countries (LMICs) focusing on the economic consequences for households of illness and health care use. These include household level impacts of direct costs (medical treatment and related financial costs), indirect costs (productive time losses resulting from illness) and subsequent household responses. It highlights that health care financing strategies that place considerable emphasis on out-of-pocket payments can impoverish households. There is growing evidence of households being pushed into poverty or forced into deeper poverty when faced with substantial medical expenses, particularly when combined with a loss of household income due to ill-health. Health sector reforms in LMICs since the late 1980s have particularly focused on promoting user fees for public sector health services and increasing the role of the private for-profit sector in health care provision. This has increasingly placed the burden of paying for health care on individuals experiencing poor health. This trend seems to continue even though some countries and international organisations are considering a shift away from their previous pro-user fee agenda. Research into alternative health care financing strategies and related mechanisms for coping with the direct and indirect costs of illness is urgently required to inform the development of appropriate social policies to improve access to essential health services and break the vicious cycle between illness and poverty.
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            BRIC’s Growing Share of Global Health Spending and Their Diverging Pathways

            BRIC’s Growing Share in Global Wealth Post-cold war developments and accelerated pace of globalization among many changes led to the creation of so called emerging markets. These classical national economies represent few among large number of developing world countries, which are distinguished by their exceptionally strong promise of rapid and long-term stable growth of gross domestic product. Either we assess it on nominal or purchase power parity (PPP) terms, four distinct economies obviously lay ahead all other rapidly developing global markets. Acronym BRIC (Brazil, Russia, India, China) forged to describe these countries brought glory to its creator Jim O’Neil, Goldman Sachs’ economist of the time (1). Since his first insight back in 2001 global recession (2) and ongoing developments were changing prospects for all four individual markets. Nevertheless, strong positive growth trend remained their common feature although with quite substantial differences in pace and balance of overall economy development (3). BRIC’s share in global wealth grew tremendously effectively quadrupling itself over past decade (4). Joint growth of this group of countries, heavily dominated by China, will remain long-term trend with clear forecasts at least up to the middle of twenty-first century (5). Consequences for National Health Systems of These Nations Each one of BRICs countries enjoyed prolonged period of geopolitical stability. Local governments via different mechanisms succeeded to use welfare of the society to improve access and quality of health care (6). Rising middle classes contributed to the higher demand for pharmaceuticals and novel medical technologies, particularly in developed urban cores. Long-term neglect of rural populations, many of them living close to poverty line, finally led to more decisive polices to tackle these issues. Health insurance coverage recorded its first serious improvements in these regions (7). Affordability of medical care to ordinary citizens was spreading although not sufficiently to follow-up disproportionate rapid growth of out of pocket spending (8). This effectively meant some serious setbacks affecting health care access to the poor (9). Many of such issues remain high on local health policy agendas and unresolved so far. Another important obstacle in mammoth sized health sectors of these nations is delivery of cutting edge treatment options to the citizens. Local innovation rate remains quite modest compared to huge research and development investment particularly characteristic of People’s Republic of China (10). Promising signs are rapidly growing frequency of scientific publications in medicine, technology patents, and strengthening of local research capabilities in terms of human resources, institutional commitment, and capital investment into equipment. Although similar positive changes are clear in all four countries, China is once again surpassing all other BRIC members with its capacity and output (11). Total Health Expenditures among BRICs in Nominal and Purchase Power Parity Terms Global health expenditure database (GHED) relying on national health accounts (NHA) system to track financial flows within national health systems of all World Health Organization (WHO) members across the globe was established since 1995 with latest official release of 2012 data (12). This is probably the most comprehensive single source allowing for international comparability of data. Observing these 18 years we might come to terms with many fine hidden patterns of health spending transformation that occurred worldwide and among the BRIC themselves. Global share of BRIC nations in total health expenditure (THE) grew from 4% ($108,938) to 12% ($858,193) in nominal terms ($USD) while change from 9% ($220,650) to 16% ($1,289,861) was even more profound in PPP terms. Joint health expenditure by BRIC nations succeeded to raise sixfold in less than two decades. Calculations of global health spending refer to 193 countries or political entities for whom complete records are available within GHED registry. Most surprising evidence comes from internal THE relationships among Brazil, India, Russian Federation, and China (Figure 1). Back in 1995, THE composition of BRICs in nominal terms was dominated by Brazil (31%) followed by China (29%) and approximately equal shares of Russia and India of 20%. Recent 2012 data point out to entirely different nominal THE landscape heavily dominated by China with 52%, followed by Brazil (17%), Russia (16%), and India (15%) all three very close to each other. THE expressed in $PPP reveals quite different picture. In 1995, Brazil held even 47% of joint spending while it was followed by China (24%), Russia (15%), and India (14%). If we observe percentage of gross domestic product (GDP) spent on health by individual countries it is easy to notice that only India remained at 4% level. Each of other three countries gained momentum of higher GDP proportion dedicated to health care today compared to situation 20 years ago. Such capital investment was led by Brazil (2.7% increase) followed by China (1.9) and Russia (0.9). Figure 1 Long-term trend on total national – level expenditure on health (THE) 1995–2012; Above: THE expressed in million current international $PPP (purchase power parity value); Beneath: THE expressed in million current US $ (nominal value); Source: Global Health Expenditure Database. Prospects of Retaining Long-Term Growth in Health Spending among the BRICs All aforementioned data point out to the several important facts. In the beginning of observation period, Brazil was dominating the BRICs landscape both in terms of nominal and PPP and percentage of gross domestic product health spending (13). Over the course of years, Brazil remained on the lead only in terms of last one (14). It is THE expressed as percentage of GDP reached 9.31% topping the list with both scale of increased and its absolute value. India, regardless of huge increase in national welfare and economic output decided to forcibly maintain its expenditure at 4% of GDP (15). Respective amount available for various health programs became much larger anyway, so it recorded successes in expanding health insurance coverage and access to medical services (16). One important advantage of India compared to its three remaining counterparts is far younger population due to delayed population aging process in this large nation. Therefore, the burden of major prosperity diseases and elderly age remains significantly easier to cope with (17). Although India’s share in BRIC’s joint THE fell significantly in percentage terms we should not forget that scope of financial means disposable for health care actually quadrupled in same period in both nominal and PPP terms. Russian Federation recorded growth of THE in all terms over past two decades but its share of BRIC’s joint THE remained at the same level (18). Nevertheless, systemic health reforms and overall economic performance were developing in the last BRIC’s member faster than anywhere else (19). The BRIC’s composition of THE observed as national level spending from year to year becomes more and more dominated by China. This is still not the case with per capita spending where Russia’s THE per capita exceeds Chines three times ($1,474 PPP in 2012) and Brazilian ($1,109 PPP in 2012) more than twice. Many of microeconomic indicators and identified health system weaknesses point out that there is long ahead of Chinese health reforms (20). Regardless of some setbacks global multinational industry of pharmaceuticals and medicinal devices will target and support largest global markets (21). The potential of all BRIC nations, led by People’s Republic of China to absorb new medical technologies and further raise demand for medical goods and services will most likely remain high in the long run (22). BRIC’s vs. OECD’s Health Expenditures Many forecasts actually point out to the growing competitiveness of BRICs compared to major OECD markets. OECD’s joint share of global health expenditure still far exceeds the one of BRICs although OECD/BRICs ratio of joint THE fell from 22 times in nominal terms in 1995 to 7 times in 2012. This same ratio expressed in PPP terms felt from ninefold larger THE in favor of OECD in 1995 to only fourfold larger THE in 2012. OECD’s proportion of global health spending fell from 91 to 81% in nominal terms and from 82 to 72% in PPP terms. The global trend of gains and losses in health spending clearly went in favor of largest emerging markets at the expense of mature, traditional high-income OECD economies (23). We should not forget that BRIC’s growth alone is not sufficient to explain existing differences. Significant part of these gains in national health budgets should be attributed to smaller N-11 emerging markets, South Africa and large number of middle- and low-income countries mostly situated in Asia, Eastern Europe, Latin America, and Africa (24). The global landscape of health care spending has clearly changed more in recent past than for the most of twentieth century (25). Beyond Tomorrow? Health policy makers are aware they should stay precautious about newly built socioeconomic welfare of many developing countries. Their national capacities to direct investment and growing capacities into the most rewarding, evidence based and cost-effective medical procedures and drugs remain very limited. Knowledge-based resource allocation still has to make roots in health policy traditions of BRICs and other emerging nations (26). Health outcomes offer final judgment on success of health care delivery to the patients in needs. Longevity gains were indeed substantial while fall in neonatal, maternal mortality, and incidence rates of communicable diseases records continuous success in these countries (27). Nevertheless, life expectancy at birth and likelihood of healthy aging remain by far higher in high-income economies with Japan topping the list (28). Facing the upcoming burden of accelerated population aging will be particularly challenging in the emerging markets where such demographic transition was far more rapid compared to most of developed societies. Official UN forecasts tell us that China will be the fastest aging among large nations for many upcoming decades (29). Very similar changes, at slightly slower pace began happening much earlier in Russia followed by Brazil. Morbidity structure of BRICs, with partial exception of India, has already changed toward the one dominated by non-communicable prosperity diseases. All of BRICs share another important geographic determinant. They do have very uneven population distribution with exceptionally large rural areas remote to most specialty hospitals and university clinics. Development of rural network of medical facilities although traditionally stronger in Russia (30), presents particular challenge to China, India, and Brazil (31). Lack of willingness in local physicians and nurses to get employed in the country side far away from more attractive career prospects in large cities, presents another obstacle leading to effective shortages of professional staff (32). Common citizens inhabiting these areas usually earn less income than those living in rich industrial cities (33). Vulnerability to catastrophic household expenditure due to illness of family member is high (34). In line with these facts, out of pocket expenditure grew tremendously in all of BRICs from $67 PPP on average in 1995 to $276 PPP in 2012. Among several causes, widespread informal payments remain significant cost driver for ordinary people (35). Faced with so many ongoing challenges it would be very hard to present any reliable future forecasts for health care affordability and sustainable financing in BRICs (36). Whether their impressive long-term efforts will bring worthy fruits in population health will probably be fully visible in the second half of twenty-first century. Conflict of Interest Statement The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
              • Record: found
              • Abstract: found
              • Article: not found

              Forecasting health expenditures: short, medium, and long (long) term.

              As the forecasting perspective changes from short to medium to long run, the appropriate measure of health spending and the choice of which variables to hold constant and which to include changes. In the short run, current dollar spending is the best unit and the primary factors affecting spending are contracts (insurance, labor) and inflation. In the medium run, real per capita health expenditures are a better measure and prior growth of income is the primary factor. In the long run, the percentage of gross domestic product is the best measure and the structure of the health system and operation of budget constraints become the most important determinants. Accuracy of +/- 1-2 percent per year is obtainable. A major issue is whether the recent moderation in the rate of growth of spending is a pause or a turning point.

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                12 February 2016
                2016
                : 7
                : 21
                Affiliations
                [1] 1Faculty of Medical Sciences, University of Kragujevac Kragujevac, Serbia
                [2] 2Risk, Insurance, and Healthcare Management Department, Temple University Philadelphia, PA, USA
                Author notes

                Edited by: Michael P. Jones, Macquarie University, Australia

                Reviewed by: Andrew Eggleston, Medtronic, Australia; Jacco Keja, IMS Health, UK

                This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2016.00021
                4751681
                26903867
                4e378b9f-682f-4f32-959c-ccfd8c18c344
                Copyright © 2016 Jakovljevic and Getzen.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 08 October 2015
                : 25 January 2016
                Page count
                Figures: 0, Tables: 1, Equations: 0, References: 12, Pages: 4, Words: 2582
                Funding
                Funded by: Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja 10.13039/501100004564
                Award ID: OI 175014
                Categories
                Pharmacology
                Data Report

                Pharmacology & Pharmaceutical medicine
                low–middle income,developing world,third world,health expenditure,medical spending

                Comments

                Comment on this article

                Related Documents Log